Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy.

IF 3.4 3区 医学 Q3 IMMUNOLOGY
Yang Zhang, Weifeng Hong, Danxue Zheng, Zongjuan Li, Yong Hu, Yixing Chen, Ping Yang, Zhaochong Zeng, Shisuo Du
{"title":"Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy.","authors":"Yang Zhang, Weifeng Hong, Danxue Zheng, Zongjuan Li, Yong Hu, Yixing Chen, Ping Yang, Zhaochong Zeng, Shisuo Du","doi":"10.1093/cei/uxae075","DOIUrl":null,"url":null,"abstract":"<p><p>Preclinical data suggest that type I interferon (IFN) responsiveness is essential for the antitumor effects of radiotherapy (RT). However, its clinical value remains unclear. This study aimed to explore this from a clinical perspective. In cohort 1, data from 152 hepatocellular carcinoma (HCC) patients who received RT were analyzed. Blood samples were taken 1 day before and 2 weeks after RT. RT was found to increase serum levels of IFN-β (a subtype of IFN-I) in HCC patients (3.42 ± 1.57 to 5.51 ± 2.11 pg/ml, P < 0.01), particularly in those with favorable responses. Higher post-RT serum IFN-β levels (≥4.77 pg/ml) were associated with better progression-free survival (HR = 0.58, P < 0.01). Cohort 2 included 46 HCC patients, including 23 who underwent preoperative RT and 23 matched control HCC who received surgical resection without RT. Formalin-fixed paraffin-embedded samples were obtained. Neoadjuvant RT significantly increased IFN-β expression in tumor tissues compared to direct surgery (8.13% ± 5.19% to 15.10% ± 5.89%, P < 0.01). Higher post-RT IFN-β (>median) indicated better disease-free survival (P = 0.049). Additionally, increased CD11c+MHCII+CD141+ antigen-presenting cell subsets and CD103+CD39+CD8+ tumor-infiltrating lymphocytes were found in the higher IFN-β group (P = 0.02, P = 0.03), which may contribute to the favorable prognosis in higher IFN-β group. Collectively, these findings suggest that IFN-β response activated by radiation may serve as a prognostic biomarker for HCC patients undergoing RT.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":" ","pages":"188-198"},"PeriodicalIF":3.4000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxae075","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Preclinical data suggest that type I interferon (IFN) responsiveness is essential for the antitumor effects of radiotherapy (RT). However, its clinical value remains unclear. This study aimed to explore this from a clinical perspective. In cohort 1, data from 152 hepatocellular carcinoma (HCC) patients who received RT were analyzed. Blood samples were taken 1 day before and 2 weeks after RT. RT was found to increase serum levels of IFN-β (a subtype of IFN-I) in HCC patients (3.42 ± 1.57 to 5.51 ± 2.11 pg/ml, P < 0.01), particularly in those with favorable responses. Higher post-RT serum IFN-β levels (≥4.77 pg/ml) were associated with better progression-free survival (HR = 0.58, P < 0.01). Cohort 2 included 46 HCC patients, including 23 who underwent preoperative RT and 23 matched control HCC who received surgical resection without RT. Formalin-fixed paraffin-embedded samples were obtained. Neoadjuvant RT significantly increased IFN-β expression in tumor tissues compared to direct surgery (8.13% ± 5.19% to 15.10% ± 5.89%, P < 0.01). Higher post-RT IFN-β (>median) indicated better disease-free survival (P = 0.049). Additionally, increased CD11c+MHCII+CD141+ antigen-presenting cell subsets and CD103+CD39+CD8+ tumor-infiltrating lymphocytes were found in the higher IFN-β group (P = 0.02, P = 0.03), which may contribute to the favorable prognosis in higher IFN-β group. Collectively, these findings suggest that IFN-β response activated by radiation may serve as a prognostic biomarker for HCC patients undergoing RT.

肝细胞癌放疗后 IFN-β 增高意味着生存率提高
临床前数据表明,I型干扰素(IFN)的反应性对放射治疗(RT)的抗肿瘤效果至关重要。然而,其临床价值仍不明确。本研究旨在从临床角度探讨这一问题。在队列 1 中,分析了 152 名接受过 RT 的肝细胞癌(HCC)患者的数据。分别在 RT 前一天和 RT 后两周采集血样。研究发现,RT 可提高 HCC 患者血清中 IFN-β(IFN-I 的一种亚型)的水平(3.42 ± 1.57 至 5.51 ± 2.11 pg/mL,p < 0.01),尤其是在那些反应良好的患者中。RT后较高的血清IFN-β水平(≥ 4.77 pg/mL)与较好的无进展生存期相关(HR = 0.58,p < 0.01)。队列 2 包括 46 例 HCC 患者,其中 23 例在术前接受了 RT 治疗,23 例与之匹配的对照组 HCC 患者在未接受 RT 治疗的情况下接受了手术切除。研究人员采集了福尔马林固定石蜡包埋样本。与直接手术相比,新辅助 RT 能显著增加肿瘤组织中 IFN-β 的表达(8.13% ± 5.19% 到 15.10% ± 5.89%,P < 0.01)。RT后IFN-β(>中位数)越高,表明无病生存率越高(p = 0.049)。此外,高IFN-β组中CD11c+MHCII+CD141+抗原递呈细胞亚群和CD103+CD39+CD8+肿瘤浸润淋巴细胞增多(p = 0.02,p = 0.03),这可能是高IFN-β组预后良好的原因。总之,这些研究结果表明,辐射激活的IFN-β反应可作为接受RT治疗的HCC患者的预后生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
2.20%
发文量
101
审稿时长
3-8 weeks
期刊介绍: Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信